<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01801904</url>
  </required_header>
  <id_info>
    <org_study_id>PACER</org_study_id>
    <secondary_id>2010-024490-39</secondary_id>
    <nct_id>NCT01801904</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer</brief_title>
  <acronym>PACER</acronym>
  <official_title>A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera G. Rummo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if panitumumab is active enough to warrant comparative&#xD;
      studies in patients with metastatic colorectal cancer that has progressed after treatment&#xD;
      with cetuximab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was amended with modification of inclusion criteria (from wild-type tumor KRAS gene&#xD;
      to wild-type RAS gene, including KRAS and NRAS exons 2, 3 and 4)&#xD;
&#xD;
      RAS mutational status of tumors of patients enrolled before amendment 1 approval will be&#xD;
      centrally revised. Patients whose tumors will result RAS mutated at the biomarkers central&#xD;
      revision, will be replaced. Therefore, the overall sample size at both the stages may be&#xD;
      higher than the one initially planned.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients alive and without disease progression</measure>
    <time_frame>2 months</time_frame>
    <description>progression of disease within 2 months from registration according to RECIST criteria, and death for any cause within 2 months from registration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>Response assessed per patients at weeks 8,16,24,32,40 and every 3 months thereafter, using RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity per patient</measure>
    <time_frame>every 2 weeks for up to 6 months</time_frame>
    <description>worst grade toxicity (according to Common Terminology Criteria for Adverse Events version 3) per patient</description>
  </secondary_outcome>
  <other_outcome>
    <measure>gene expression on tumor tissue</measure>
    <time_frame>one year</time_frame>
    <description>exploratory analysis of tumor-tissue for biological or genomic determinants of outcome of BRAF and P13K mutation status, EGFR and PTEN expression status</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity</description>
    <arm_group_label>Panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologic diagnosis of metastatic colorectal adenocarcinoma&#xD;
&#xD;
          -  a wild-type RAS tumor (mutational status has to be determined by an experienced&#xD;
             laboratory using validated test methods for detection of KRAS exons 2, 3, and 4, and&#xD;
             NRAS exons 2, 3, and 4&#xD;
&#xD;
          -  Failure from previous treatment with fluoropyrimidine, oxaliplatin and irinotecan.&#xD;
             Patients may or may not have been treated with bevacizumab.&#xD;
&#xD;
          -  Documented disease progression following a treatment with cetuximab in patients who&#xD;
             showed either an objective response after 8 weeks or stable disease after 16 weeks of&#xD;
             cetuximab treatment.&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  ECOG Performance Status 0-2&#xD;
&#xD;
          -  Neutrophils at least 1,500 mm3, platelets at least 100,000 mm3, and hemoglobin at&#xD;
             least 9 g/dL&#xD;
&#xD;
          -  Bilirubin level less than 1.5 times ULN&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) not greater than 2.5 times ULN (or 5 times ULN in presence&#xD;
             of liver metastasis)&#xD;
&#xD;
          -  Serum creatinine less than 1.5 times ULN&#xD;
&#xD;
          -  Effective contraception, if the risk of conception exists&#xD;
&#xD;
          -  Life expectancy at least 3 months&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic brain metastasis&#xD;
&#xD;
          -  Interstitial pneumonitis or pulmonary fibrosis&#xD;
&#xD;
          -  Any other malignancies within 5 years (except for adequately treated carcinoma in situ&#xD;
             of the cervix or non melanoma skin cancer)&#xD;
&#xD;
          -  Chemotherapy, radiotherapy or immunotherapy within the past 4 weeks&#xD;
&#xD;
          -  Any unstable systemic disease (including active infections, any significant hepatic,&#xD;
             renal or metabolic disease), metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding that contraindicates the use of study drugs or render the&#xD;
             patient at high risk from treatment complications&#xD;
&#xD;
          -  Subject pregnant or breast feeding, or planning to become pregnant within 6 months&#xD;
             after the end of treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Daniele, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Sanitaria Rummo, Benevento, Division of Medical Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute Naples, Italy; Director Clinical Trials Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second University of Naples, Italy; Chair of Medical Statistics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Gasbarrini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit√† Cattolica del S. Cuore, Policlinico Gemelli, Roma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giacomo Carteni', M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Antonio Cardarelli, Napoli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Rummo</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa Sollievo Sofferenza</name>
      <address>
        <city>S. Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2013</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cetuximab-refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

